|
GSK PLC on Wednesday announced that its RSV vaccine Arexvy has become the first EU-backed vaccine against the respiratory syncytial virus for adults aged 60 and older. The European Commission authorised the jab, the Brentford, London-based pharmaceutical company said. The approval comes a little more than a month after it was approved in the US. First launches of the vaccine in the EU are planned ahead of the 2023/2024 RSV season, which typically starts in autumn. RSV is a common contagious virus affecting the lungs and breathing passages. Chief Scientific Officer Tony Wood said: ‘Thousands of older adults across Europe suffer serious respiratory illness due to RSV each year. This authorisation for Arexvy means eligible adults can be vaccinated against RSV disease for the first time, reinforcing GSK’s long history of vaccine innovation. Our strong manufacturing capability and scale, including from our vaccine manufacturing site in Belgium, means we are ready to deliver the vaccine as countries begin to launch.’ Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
